Zachary C Hartman
Overview
Explore the profile of Zachary C Hartman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1791
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marek R, Halabi S, Wang M, McBane J, Wei J, Wang T, et al.
Vaccines (Basel)
. 2024 Nov;
12(11).
PMID: 39591176
: Androgen receptor (AR) expression and signaling are critical for the progression of prostate cancer and have been the therapeutic focus of prostate cancer for over 50 years. While a...
2.
Trotter T, Wilson A, McBane J, Dagotto C, Yang X, Wei J, et al.
Cancer Res Commun
. 2024 Apr;
4(4):1050-1062.
PMID: 38592453
Significance: Multitolerant NoGlow mice enable tracking and gene manipulation of transplanted tumor cells without immune-mediated rejection, thus providing a platform to investigate novel mechanisms of adaptive immunity related to metastasis,...
3.
Dailey G, Rabiola C, Lei G, Wei J, Yang X, Wang T, et al.
Hum Vaccin Immunother
. 2024 Feb;
20(1):2309693.
PMID: 38330990
ER+ breast cancers (BC) are characterized by the elevated expression and signaling of estrogen receptor alpha (, which renders them sensitive to anti-endocrine therapy. While these therapies are clinically effective,...
4.
Bhagat A, Lyerly H, Morse M, Hartman Z
Hum Vaccin Immunother
. 2023 Dec;
19(3):2291857.
PMID: 38087989
Carcinoembryonic antigen (CEA) is a glycosylated cell surface oncofetal protein involved in adhesion, proliferation, and migration that is highly upregulated in multiple carcinomas and has long been a promising target...
5.
Trotter T, Dagotto C, Serra D, Wang T, Yang X, Acharya C, et al.
JCI Insight
. 2023 Oct;
8(22).
PMID: 37847565
Approximately 30% of breast cancer survivors deemed free of disease will experience locoregional or metastatic recurrence even up to 30 years after initial diagnosis, yet how residual/dormant tumor cells escape...
6.
Crosby E, Hartman Z, Lyerly H
Clin Cancer Res
. 2023 Jul;
29(17):3256-3258.
PMID: 37428103
A vaccine targeting HER2, a nonmutated but overexpressed tumor antigen, readily primed T cells for ex vivo expansion and adoptive transfer with minimal toxicity. This regimen led to intramolecular epitope...
7.
Morse M, Crosby E, Force J, Osada T, Hobeika A, Hartman Z, et al.
Cancer Gene Ther
. 2023 Feb;
30(6):803-811.
PMID: 36765179
Therapeutic cancer vaccines, designed to activate immune effectors against tumor antigens, utilize a number of different platforms for antigen delivery. Among these are messenger RNAs (mRNA), successfully deployed in some...
8.
Dailey G, Crosby E, Hartman Z
Cancer Gene Ther
. 2022 Jul;
30(6):794-802.
PMID: 35821284
The development and success of RNA-based vaccines targeting SARS-CoV-2 has awakened new interest in utilizing RNA vaccines against cancer, particularly in the emerging use of self-replicating RNA (srRNA) viral vaccine...
9.
Tsao L, Crosby E, Trotter T, Wei J, Wang T, Yang X, et al.
JCI Insight
. 2022 Feb;
7(6).
PMID: 35167491
Two HER2-specific mAbs, trastuzumab and pertuzumab (T+P), combined with chemotherapy comprise standard-of-care treatment for advanced HER2+ breast cancers (BC). While this antibody combination is highly effective, its synergistic mechanism-of-action (MOA)...
10.
Osada T, Crosby E, Kaneko K, Snyder J, Ginzel J, Acharya C, et al.
Mol Cancer Ther
. 2021 Oct;
21(1):217-226.
PMID: 34675120
A noninvasive test to discriminate indolent prostate cancers from lethal ones would focus treatment where necessary while reducing overtreatment. We exploited the known activity of heat shock protein 90 (Hsp90)...